KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Amortization - Intangibles (2016 - 2025)

Historic Amortization - Intangibles for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $1.2 billion.

  • Pfizer's Amortization - Intangibles fell 678.35% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year decrease of 456.3%. This contributed to the annual value of $5.3 billion for FY2024, which is 1197.97% up from last year.
  • As of Q3 2025, Pfizer's Amortization - Intangibles stood at $1.2 billion, which was down 678.35% from $1.2 billion recorded in Q2 2025.
  • Pfizer's Amortization - Intangibles' 5-year high stood at $1.3 billion during Q3 2024, with a 5-year trough of $822.0 million in Q3 2022.
  • Its 5-year average for Amortization - Intangibles is $1.1 billion, with a median of $1.2 billion in 2023.
  • As far as peak fluctuations go, Pfizer's Amortization - Intangibles plummeted by 1508.26% in 2022, and later surged by 4403.89% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Amortization - Intangibles stood at $968.0 million in 2021, then dropped by 15.08% to $822.0 million in 2022, then surged by 54.14% to $1.3 billion in 2023, then grew by 3.55% to $1.3 billion in 2024, then decreased by 6.78% to $1.2 billion in 2025.
  • Its Amortization - Intangibles stands at $1.2 billion for Q3 2025, versus $1.2 billion for Q2 2025 and $1.2 billion for Q1 2025.